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Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus
at six months after treatment. However, the incidence of clinical events during long term follow up of
patients with sustained virological response is still poorly documented and may differ between the Eastern
and Western world.
Aims: To assess clinical end points during long term follow up of European patients with a sustained
virological response to interferon monotherapy.
Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of
interferon treatment for chronic hepatitis C.
Results: A total of 286 sustained virological responders and 50 biochemical responders (detectable virus
but normal alanine aminotransferase levels) were followed up for 59 months. Fifteen sustained virological
responders (5.2%) had cirrhosis before treatment and 112 (39%) had genotype 1. The late virological
relapse rate after five years of follow up was 4.7% (95% confidence interval (CI) 2.0–7.4) among sustained
virological responders; all late relapses occurred within four years after treatment. Among sustained
virological responders, the rate of decompensation after five years of follow up was 1.0% (95% CI 0.0–
2.3) and none developed hepatocellular carcinoma (HCC). Survival was comparable with the general
population, matched for age and sex, the standard mortality ratio being 1.4 (95% CI 0.3–2.5). Clinical
outcome of patients with cirrhosis was similar to other sustained virological responders. For biochemical
responders, the rates of development of decompensation and HCC during long term follow up were 9.1%
(95% CI 0.5–17.7) and 7.1% (95% CI 0–15.0), respectively.
Conclusions: Five year survival of European sustained virological responders was similar to the overall
population, matched for age and sex. No HCCs were detected during long term follow up.
C
hronic infection with the hepatitis C virus (HCV) can
lead to decompensated liver cirrhosis and hepatocel-
lular carcinoma (HCC). However, treatment of hepatitis
C is based on surrogate end points, and evaluation of
treatment for clinical end points has only slowly been forth-
coming due to the slow course of the disease and the small
number of clinical events in patients treated for hepatitis C.
Protocolled studies use sustained virological response as
the key outcome measure for hepatitis C treatment. This
sustained virological response is defined as no detectable
HCV-RNA in serum at six months after treatment. The aim of
this study was to determine the long term clinical outcome of
sustained virological responders who had been treated in
protocolled studies.
PATIENTS AND METHODS
Study design
All European centres that had published long term data on
patients treated for chronic hepatitis C before 1997 were
invited to participate in the protocol and to include patients
with response to treatment.
Additional entry criteria were study follow up longer than
one year and availability of HCV-RNA data. Nine centres met
these criteria. Patients from eight European hepatology units
were included in the study.1–12
Patient selection
Data from 343 consecutive chronic hepatitis C patients with
response to interferon monotherapy were obtained. All
patients had participated in protocolled studies (clear cohort
or randomised controlled trial). Data were collected on
separate case record forms, one per patient, by the local
investigator. The case record forms were sent to the
coordination centre in Rotterdam where data were entered
into a central database. Before the data were entered, they
were checked and, in case of doubt, contact was made with
the local investigator.
Data recorded
Information was obtained on demographics (date of birth,
sex) and on details of treatment (initial dose, duration of
treatment, and total dose of interferon). Virological data
(genotype, viraemia) and biochemical data (platelet count,
bilirubin, albumin, and transaminase levels) were measured
in certified laboratories of participating hospitals and added
to the case record form by the local investigator. Centrally,
results were corrected for local normal values. Results of pre-
and post-treatment liver biopsies were recorded using the
HAI score for activity and the Knodell score for fibrosis.13 All
centres used polymerase chain reaction (PCR) methods with
a detection limit of 100 copies/ml, except for one centre
where PCR with a detection limit of 1000 copies/ml was used
before 1998. No late virological relapses were reported from
Abbreviations: HCV, hepatitis C virus; RNA, ribonucleic acid; MU,
mega unit; IFN, interferon; PCR, polymerase chain reaction; HCC,
hepatocellular carcinoma; ALT, alanine aminotransferase
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this centre after introduction of a test with a sensitivity of
100 copies/ml.
Follow up data were recorded every six months and
included alanine aminotransferase (ALT) levels, HCV-RNA,
and the occurrence of clinical events (decompensation, HCC,
death).
Patients were considered to have decompensation if they
showed any of the following symptoms: ascites, bleeding
varices, jaundice, or hepatic encephalopathy. Patients were
classified as having developed cirrhosis on the basis of
ultrasound (nodular contour, diminished hepatopetal flow,
collaterals), serology (platelets ,80000, albumin ,35 g/l,
clotting factors,50%), or liver biopsy. Patients were con-
sidered to have HCC if the a fetoprotein level was .400 and
ultrasound confirmed a focal lesion, or if biopsy proved so.
Death was classified as liver related or liver unrelated.
Sustained virological response was defined as no detectable
HCV-RNA at the end of treatment and after six months of
follow up. Patients with normal ALT levels at these time
points, but with detectable HCV-RNA at the end of treatment
or six months thereafter, were referred to as biochemical
responders. Sustained virological responders were considered
to have a late virological relapse if HCV-RNA was detectable
on any occasion after six months of follow up, confirmed by
either a second PCR or elevation of ALT levels above the
upper limit of normal.
Statistical analysis
To evaluate factors of influence on late virological relapse,
univariate and multivariate Cox regression analyses were
performed. The Kaplan-Meier method was used to evaluate
the five year late relapse rate and to determine the rate of
occurrence of clinical events during five years of follow up.
The number of expected deaths and the expected survival
probability were calculated based on sex and age ranked
mortality among the Dutch general population, which is
similar to most European countries.14 The standard mortality
ratio was calculated by dividing the observed number of
deaths by the expected number of deaths.
We used multiple regression analysis to identify risk factors
for fibrosis progression.
Statistical analyses were performed using SPSS for
Windows (SPSS Inc, Chicago, Illinois, USA). All analyses
were performed by the Meta-Analysis of Individual Data
group in Rotterdam (BEH, SWS, BJV), which is experienced
in the conduct of such studies.
RESULTS
Study population
Data were obtained for 343 patients treated for chronic
hepatitis C. A total of 286 patients had a sustained virological
response and 50 had a biochemical response. Seven patients
did not fit the entry criterion of HCV-RNA data availability at
the end of treatment and after six months of follow up and
were excluded from further analysis.
Characteristics of sustained virological responders and
biochemical responders are shown in table 1. Patients had
been treated with recombinant interferon a2a, a2b, or natural
interferon monotherapy. Patients were treated for an average
duration of 39 weeks (range 11–96). Patients with genotype 1
were treated longer (mean duration 41 weeks v. 38 weeks in
other genotypes; p,0.01) and received a higher total dose of
interferon (581 mega units (MU) v 525 MU in other
genotypes; p,0.01, Mann-Whitney U test).
Table 1 Patient characteristics
Sustained virological
responders
Biochemical
responders
p Value
(Mann Whitney/
x2)
No 286 50
Age (y) (mean (range)) 41 (17–72) 45 (23–72) 0.04
Male (n (%)) 169 (59) 26 (52) 0.35
Follow up (months) (mean (range)) 59 (12–120) 59 (6–96) 0.99
Total dose of interferon (MU) (mean (SD)) 550 (283) 469 (290) 0.05
Genotype 1 (n (%)) 112 (39) 21 (42) 0.71
Cirrhosis (n (%)) 15 (5.2) 11 (22) 0.00
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Sustained virological responders
Of 286 sustained responders, 15 patients had cirrhosis before
the start of treatment, as determined by liver biopsy.
Two patients presented with decompensated cirrhosis after
30 and 60 months of follow up (fig 1). These patients were
hepatitis B surface antigen negative and HCV-RNA negative,
and no other risk factors for liver disease were reported. The
latter patient died of decompensated cirrhosis. Five other
patients died of non-liver related causes. One patient died of
lung cancer and two patients died of trauma; another patient
died of cardiovascular complications and one patient died of
a haemolytic uraemic syndrome.
The standard mortality ratio of sustained responders was
1.4 (95% confidence interval (CI) 0.3–2.5) (table 2), and there
was no statistically significant difference in mortality
between sustained virological responders and the general
population, matched for age and sex (fig 2).
Biochemical responders
Fifty patients had normal transaminase levels at the end of
follow up and six months after treatment while HCV-RNA
was still detectable. Of these biochemical responders, three
patients died during long term follow up, all of liver related
causes. The occurrence of decompensation and HCC among
biochemical responders was 9.1% (95% CI 0.5–17.7) and 7.1%
(95% CI 0–15.0), respectively (fig 1). Biochemical responders
were older and had a higher prevalence of cirrhosis. Although
there was a trend to a higher standard mortality ratio
(corrected for age and sex) in biochemical responders after
five years of follow up, the difference did not reach statistical
significance (table 2).
Liver histology
One hundred and twenty five patients (110 sustained
virological responders and 15 biochemical responders) under-
went liver biopsy both before and after treatment. Mean time
between these two biopsies was 1.6 years (SD 0.8). Thirty
two sustained virological responders (29%) and none of the
biochemical responders showed regression of fibrosis.
Progression of fibrosis was seen in six sustained virological
responders (5%) and in three biochemical responders (20%)
(table 3). Baseline characteristics of sustained virological
responders and biochemical responders who underwent two
biopsies were different, with sustained virological responders
being younger (mean 39 (SD 13) v 47 (14) years), having a
lower mean pretreatment fibrosis stage (1.75 (1.1) v 2.5
(1.4)), and having a shorter time between the two biopsies
(1.5 (0.6) v 2.3 (1.5) years). Therefore, we performed a
multiple regression analysis to determine independent risk
factors for progression of fibrosis. Fibrosis progression was
associated with older age, lower pretreatment fibrosis score,
and biochemical response rather than sustained virological
response (table 4).
Late relapsers
Twelve sustained responders had a late virological relapse
(fig 3). In six patients (50%), late virological relapse was
accompanied by an elevation in transaminase levels.
Multivariate Cox regression analysis did not show any
pretreatment factors to be associated with an increased risk
for late virological relapse. None of the late relapsers
developed decompensation or HCC during follow up.
DISCUSSION
This large European study allows, for the first time, an
approximation of the incidence of clinical events during long
term follow up of sustained virological responders in Europe.
The most important finding is that clinical events are rare in
this population, indicating that sustained virological respon-
ders have an excellent prognosis.
The largest European study to date describing clinical
outcome in sustained responders to interferon treatment did
not report any events among 74 patients followed up for
2.7 years.15 Two other European studies, involving seven and
56 sustained responders, also showed no clinical events
during 4.6 and 5.2 years of follow up, respectively.8 16 Bruno
et al described 32 sustained responders of whom one cirrhotic
patient developed HCC.17 Although another HCC has been
reported recently in a Western sustained responder,18 these
cases seem to be rare and limited to patients with cirrhosis. In
the present study, no HCCs occurred during long term follow
Table 2 Standard mortality ratios (SMR) for sustained virological responders and
biochemical responders
n Deaths
Deaths
expected SMR 95% CI
Sustained virological responders 286 6 4.3 1.4 0.3–2.5
Biochemical responders 50 3 0.5 5.6 0.0–12.6
95% CI, 95% confidence interval.
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Figure 2 Kaplan-Meier curve showing survival of sustained virological
responders compared with the age and sex matched general population.
Table 3 Change in fibrosis according to response to
treatment in patients who underwent pretreatment and
post-treatment biopsies
SVR BR
No of patients 110 15
2 points progression 3 (3%) 1 (7%)
1 point progression 3 (3%) 2 (13%)
No change 72 (65%) 12 (80%)
1 point regression 23 (21%) 0 (0%)
2 points regression 9 (8%) 0 (0%)
SVR, sustained virological responders; BR, biochemical responders.
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up. According to several large studies, the yearly incidence of
HCC among Japanese sustained virological responders still
varies between 0.02% and 0.5% per year19–26; the difference in
the incidence of HCC between East and West apparently
persists in conditions without detectable viral replication.
The lowest rates in Japan were reported by Yoshida et al,
with one HCC among 817 sustained responders during
5.4 years of follow up.26 The highest incidence of HCC
reported among sustained responders in Japan was by
Kasahara et al who reported five HCCs among 313 sustained
virological responders followed up for three years.22
Fifteen cirrhotic patients were included in this study. Only
two patients with decompensated cirrhosis were reported.
Among untreated cirrhotics, occurrence of clinical events of
38% (28% decompensation and 10% HCC) would be
expected, according to Fattovich and colleagues.27 These
results suggest, but do not prove, a change in the natural
course of chronic hepatitis C. Further studies, including more
cirrhotics, will be necessary to investigate the effect of
treatment on the natural course of chronic hepatitis C.
In this study, sustained virological response was associated
with a decrease in fibrosis score. Similar findings have been
reported for sustained responders to pegylated interferon.28 29
Previous studies have shown that regression of fibrosis can
also occur in biochemical responders and non-responders to
interferon. In common with our study, sustained virological
responders show the highest rate of regression.30 Because of
the large proportion of sustained virological responders that
showed regression of fibrosis and the low incidence of clinical
events in these patients, in our view, non-cirrhotic patients
with a sustained virological response can be regarded as
cured.
A limitation of our study is that all patients had been
treated with interferon monotherapy whereas the current
standard therapy for chronic hepatitis C is pegylated
interferon with ribavirin. This current standard however
dates from 2002 and long term follow up data of peginter-
feron and ribavirin were not available at the time of this
study.31 In general, combination therapy leads to higher
sustained virological response rates32 33 and also the late
relapse rate seems to decrease. In this study with data on
interferon monotherapy, the late relapse rate was 4.7% (95%
CI 2.0–7.4); Camma et al reported 8.7% in a meta-analysis of
14 trials with interferon monotherapy.34 After four years of
follow up of treatment with interferon and ribavirin, late
virological relapse rates of 3% (95% CI 1.4–4.6) and 1% (95%
CI 0–2.0) have been reported for patients treated for 24 weeks
and 48 weeks, respectively.18 After treatment with pegylated
interferon with or without ribavirin, a late relapse rate of
0.8% was reported after four years of follow up.35 The
possibility of reinfection could not be ruled out in our cohort
as data on risk behaviour and concordance of genotypes were
not available. However, introduction of more sensitive PCR
methods may also have contributed to a decrease in late
virological relapse over time. It is possible that with an
insensitive assay, patients with low viraemia are regarded as
sustained virological responders.
As the late relapse rate seems to decrease with newer
treatment regimens, long term clinical outcomes may be
similar or even better than results obtained with interferon
monotherapy. Therefore, in our opinion, the favourable
clinical outcome of sustained virological responders is likely
to hold true in the era of pegylated interferon and ribavirin.
In conclusion, the long term clinical outcome of patients
with a sustained response to interferon is favourable. Five
year survival of European sustained virological responders
was similar to the general population, matched for age and
sex, and no HCCs were detected during long term follow up.
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Table 4 Multiple regression analysis assessing risk factors for fibrosis progression
Hazard ratio
95% CI
p ValueLower Upper
Male sex 0.02 20.29 0.34 0.86
Age 0.29 0.00 0.03 0.01
Fibrosis stage pretreatment 20.50* 20.52 20.21 ,0.01
Activity score pretreatment 0.09 20.04 0.12 0.37
Time between biopsies 0.08 20.12 0.29 0.40
Biochemical response to therapy v sustained virological
response
0.31` 0.30 1.49 ,0.01
*Higher pretreatment fibrosis stage associated with a smaller chance of fibrosis progression, while older age and
biochemical response` were associated with a higher chance of fibrosis progression.
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Figure 3 Kaplan-Meier curve showing late virological relapse among
sustained virological responders. No late virological relapses were seen
after four years of follow up, the maximal delay between the last
negative polymerase chain reaction (PCR) and the first positive PCR
result being 12 months.
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